ETF overview
The Invesco Nasdaq Biotechnology ETF (IBBQ) seeks to mirror the investment performance of the Nasdaq Biotechnology Index. To achieve this, the Fund generally dedicates at least 90% of its total capital to the securities that make up this benchmark index. The underlying Index itself is specifically designed to gauge the returns of biotechnology and pharmaceutical companies whose shares are publicly traded on the Nasdaq Stock Market. Both the ETF and its corresponding Index undergo a yearly review and update of their composition each December, and their weightings are adjusted quarterly in March, June, September, and December.
Fund facts
- Expense ratio
- 0.19%
- Fund assets
- 114.51M USD (all share classes)
- Issuer
- Invesco
- Inception date
- Jun 11, 2021
- Number of holdings
- 254
Breakdown
Holdings (254)
| Name | Ticker | Weight |
|---|---|---|
| Gilead Sciences Inc | GILD | 8.75% |
| Amgen Inc | AMGN | 8.22% |
| Vertex Pharmaceuticals Inc | VRTX | 7.60% |
| Moderna Inc | MRNA | 6.29% |
| Regeneron Pharmaceuticals Inc | REGN | 5.36% |
| Revolution Medicines Inc | RVMD | 2.70% |
| Illumina Inc | ILMN | 2.69% |
| Biogen Inc | BIIB | 2.32% |
| Alnylam Pharmaceuticals Inc | ALNY | 2.09% |
| Royalty Pharma PLC | RPRX | 1.77% |
| and 241 more | ||
Similar ETFs
- Invesco NASDAQ Biotech UCITS ETFSBIO.L · Overlap 100% · Expense ratio 0.40%
- iShares Nasdaq US Biotechnology UCITS ETFBTEC.L · Overlap 100% · Expense ratio 0.35%
- MiraeAsset TIGER NASDAQ BIO ETF203780.KS · Overlap 100% · Expense ratio 0.30%
- iShares Biotechnology ETFIBB · Overlap 86% · Expense ratio 0.44%
- VanEck Biotech ETFBBH · Overlap 58% · Expense ratio 0.35%
- State Street SPDR S&P Biotech ETFXBI · Overlap 43% · Expense ratio 0.35%
- Invesco Biotechnology & Genome ETFPBE · Overlap 39% · Expense ratio 0.59%
- First Trust Nasdaq Pharmaceuticals ETFFTXH · Overlap 39% · Expense ratio 0.60%
Overlap is the share of assets the two funds hold in common.
Historical returns do not guarantee future returns. This is not investment advice.
- Expense ratio
- 0.19%
- Fund assets
- 114.51M USD (all share classes)
- Issuer
- Invesco
- Inception date
- Jun 11, 2021
- Number of holdings
- 254
| Name | Ticker | Weight |
|---|---|---|
| Gilead Sciences Inc | GILD | 8.75% |
| Amgen Inc | AMGN | 8.22% |
| Vertex Pharmaceuticals Inc | VRTX | 7.60% |
| Moderna Inc | MRNA | 6.29% |
| Regeneron Pharmaceuticals Inc | REGN | 5.36% |
| Revolution Medicines Inc | RVMD | 2.70% |
| Illumina Inc | ILMN | 2.69% |
| Biogen Inc | BIIB | 2.32% |
| Alnylam Pharmaceuticals Inc | ALNY | 2.09% |
| Royalty Pharma PLC | RPRX | 1.77% |
| and 241 more | ||
The Invesco Nasdaq Biotechnology ETF (IBBQ) seeks to mirror the investment performance of the Nasdaq Biotechnology Index. To achieve this, the Fund generally dedicates at least 90% of its total capital to the securities that make up this benchmark index. The underlying Index itself is specifically designed to gauge the returns of biotechnology and pharmaceutical companies whose shares are publicly traded on the Nasdaq Stock Market. Both the ETF and its corresponding Index undergo a yearly review and update of their composition each December, and their weightings are adjusted quarterly in March, June, September, and December.
- Invesco NASDAQ Biotech UCITS ETFSBIO.L · Overlap 100% · Expense ratio 0.40%
- iShares Nasdaq US Biotechnology UCITS ETFBTEC.L · Overlap 100% · Expense ratio 0.35%
- MiraeAsset TIGER NASDAQ BIO ETF203780.KS · Overlap 100% · Expense ratio 0.30%
- iShares Biotechnology ETFIBB · Overlap 86% · Expense ratio 0.44%
- VanEck Biotech ETFBBH · Overlap 58% · Expense ratio 0.35%
- State Street SPDR S&P Biotech ETFXBI · Overlap 43% · Expense ratio 0.35%
- Invesco Biotechnology & Genome ETFPBE · Overlap 39% · Expense ratio 0.59%
- First Trust Nasdaq Pharmaceuticals ETFFTXH · Overlap 39% · Expense ratio 0.60%
Overlap is the share of assets the two funds hold in common.
Unlock all ETF data
Sign up for FreeUnlock all ETF data
Sign up for Free